Autolus reports Q1 AUCATZYL revenue $9.0M; UK MHRA approval for r/r B-ALL

Autolus Therapeutics plc

2025-Q1 EPS reported -$0.26 revenue$8,982,000

Q1 2025 AUCATZYL net product revenue $9.0M, first quarter of launch.
UK MHRA granted conditional marketing authorization for AUCATZYL in r/r B-ALL.
Net loss $70.2M ($0.26 per share) vs $52.7M ($0.24) in Q1 2024.
Cash & marketable securities $516.6M; company well-capitalized for launch and trials.
Phase 1 CARLYSLE data: 3/6 SLE patients complete renal response; Phase 2 LN trial by year-end.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.